Obalon Therapeu…
ProfileJobs

Obalon Therapeutics

Suggest Edit
    • Healthhealthtechmedical devicestherapy
    Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
    Revenue(FY, 2017)
    $9.9 M
    Market capitalization(2018-04-20)
    $56.6 M
    Type
    Public
    HQ
    Carlsbad, US
    Founded
    2008
    Size (employees)
    91 (est)
    Website
    obalon.com
    Obalon Therapeutics was founded in 2008 and is headquartered in Carlsbad, US
    Report incorrect company information

    Key People/Management at Obalon Therapeutics

    Mark Brister

    Mark Brister

    VP of R&D
    Nooshin Hussainy

    Nooshin Hussainy

    Financial Controller

    Obalon Therapeutics Office Locations

    Obalon Therapeutics has an office in Carlsbad
    Carlsbad, US (HQ)
    f 5421 Avenida Encinas
    Show all (1)
    Report incorrect company information

    Obalon Therapeutics Financials and Metrics

    Obalon Therapeutics Financials

    Obalon Therapeutics's revenue was reported to be $9.91 m in FY, 2017
    USD

    Revenue (FY, 2017)

    		9.9 m

    Gross profit (FY, 2017)

    		5.1 m

    Gross profit margin (FY, 2017), %

    		51.3%

    Net income (FY, 2017)

    		(34.8 m)

    EBIT (FY, 2017)

    		(34.4 m)

    Market capitalization (20-Apr-2018)

    		56.6 m

    Cash (31-Dec-2017)

    		21.1 m
    Obalon Therapeutics's current market capitalization is $56.6 m.
    Annual
    USDFY, 2016FY, 2017

    Revenue

    		9.9 m

    Cost of goods sold

    		2.8 m4.8 m

    Gross profit

    		(2.8 m)5.1 m

    Gross profit Margin, %

    		51%
    Quarterly
    USDQ3, 2016Q1, 2017Q2, 2017

    Revenue

    		773 k1.5 m2 m

    Cost of goods sold

    		644 k823 k990 k

    Gross profit

    		129 k649 k973 k

    Gross profit Margin, %

    		17%44%50%
    show all
    Annual
    USDFY, 2016FY, 2017

    Cash

    		73 m21.1 m

    Accounts Receivable

    		2.9 m4.2 m

    Inventories

    		827 k1.4 m

    Current Assets

    		78.1 m51.8 m
    Quarterly
    USDQ3, 2016Q1, 2017Q2, 2017

    Cash

    		2.3 m41.7 m5.8 m

    Accounts Receivable

    		1 m1.8 m

    Inventories

    		438 k928 k747 k

    Current Assets

    		18 m69.7 m63.9 m
    show all
    Annual
    USDFY, 2016FY, 2017

    Net Income

    		(20.5 m)(34.8 m)

    Depreciation and Amortization

    		192 k330 k

    Inventories

    		(464 k)(591 k)

    Accounts Payable

    		46 k624 k
    Quarterly
    USDQ3, 2016Q1, 2017

    Net Income

    		(5.3 m)(7.7 m)

    Inventories

    		438 k928 k

    Accounts Payable

    		1.1 m823 k
    show all
    USDY, 2017

    Revenue/Employee

    		108.9 k

    Financial Leverage

    		1.5 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Primrose Therapeutics
    Health - Private
    Penumbra
    Health - Public
    ElectroCore
    Health - Private
    ReShape Lifesciences
    Health - Public
    Compare competitors
    Download PDF